Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial
The effect of ertugliflozin was consistent across the spectrum of total investigator-reported HF AEs and was similar in magnitude to adjudicated HHF events.
Authors
- Ambarish Pandey (ORCID: https://orcid.org/0000-0001-9651-3836)
- Ira Gantz (ORCID: https://orcid.org/0000-0002-6565-7113)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Samuel E. Dagogo-Jack (ORCID: https://orcid.org/0000-0001-5318-9677)
- Robert Frederich (ORCID: https://orcid.org/0000-0002-5175-3112)
- Urszula Masiukiewicz
- Willy Wynant (ORCID: https://orcid.org/0000-0001-7014-3515)
- Nilo B. Cater (ORCID: https://orcid.org/0000-0001-5868-8643)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-5698-7946)
- Ahmed A. Kolkailah (ORCID: https://orcid.org/0000-0002-3327-1718)
- Richard E. Pratley
- Darren K. McGuire
- James P. Mancuso (ORCID: https://orcid.org/0000-0002-5722-1360)
- Christopher P. Cannon
Institutions
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Parkland Health & Hospital System (US)
- Karolinska University Hospital (SE)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Pfizer (United States) (US)
- University of Toronto (CA)
- Southwestern Medical Center (US)
- Syneos Health (United States) (US)
- Translational Research Institute for Metabolism and Diabetes (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1002/ejhf.3511
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Pfizer